A Case Report on the Effect of Everolimus in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex

Huma M Paika, Yull E. Arriaga, Anthony Setiawan

Abstract


Tuberous Sclerosis (TS) is a well known disorder which manifests with benign tumors in various organ systems, including angiomyolipomas (AML) of the kidneys. The mTOR inhibitors have emerged as a potential systemic treatment strategy to halt the growth of renal angiomyolipomas and to prevent life threatening complications such as bleeding. This report shows that everolimus treatment may have an impact on size and density of renal AML lesions which may lead to prevention or delay the development of renal cell carcinoma as well as prevent bleeding from the renal AML lesions. A 20-year-old Hispanic female and a 24-year-old Asian female both with sporadic TS were administered daily oral everolimus therapy. Both showed stability in their renal AML lesions and notable improvement of their extra-renal TS manifestations. Treatment with daily everolimus may lead to reduction in size and/or decreases in density or renal AML lesions. This may have an impact on the risk of developing renal cell carcinoma as well as preventing bleeding from renal AML lesions.




J Med Cases. 2014;5(3):129-136
doi: http://dx.doi.org/10.14740/jmc1665w

Keywords


mTOR inhibitor; Tuberous sclerosis; Angiomyolipoma; Everolimus

Full Text: HTML PDF
 

Browse  Journals  

     

Journal of clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 

 

 

 

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.            
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.